Last reviewed · How we verify
DWJ1319
DWJ1319 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.
DWJ1319 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting or sarcopenia (phase 3 development).
At a glance
| Generic name | DWJ1319 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Selective Androgen Receptor Modulator (SARM) |
| Target | Androgen Receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
SARMs like DWJ1319 are designed to selectively activate androgen receptors in muscle and bone tissue while avoiding activation in prostate and other tissues that mediate unwanted androgenic effects. This tissue selectivity aims to provide anabolic benefits such as increased muscle mass and bone density with a reduced side effect profile compared to traditional androgens or anabolic steroids.
Approved indications
- Muscle wasting or sarcopenia (phase 3 development)
Common side effects
- Testosterone suppression
- Liver enzyme elevation
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWJ1319 CI brief — competitive landscape report
- DWJ1319 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI